Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer

Salma K. Jabbour; Ki Hyeong Lee; Nikolaj Frost; В. В. Бредер; Dariusz M. Kowalski; Theodore Pollock; E. Levchenko; Noemı́ Reguart; Alex Martínez‐Martí; Baerin Houghton; Jean-Baptiste Paoli; Sufia Safina; Keunchil Park; Takefumi Komiya; Amy Sanford; Vishal Boolell; Hong Liu; Ayman Samkari; Steven M. Keller; Martin Reck

doi:10.1001/jamaoncol.2021.2301

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

The findings of this phase 2, nonrandomized, 2-cohort study suggest promising antitumor activity of pembrolizumab plus cCRT and manageable safety in patients with previously untreated, locally advanced, stage III NSCLC.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Jabbour et al. (2021) studied this question.

synapsesocial.com/papers/69de7daa210a0977fce945e7 https://doi.org/10.1001/jamaoncol.2021.2301

View Full Paper

Ask AI

Bookmark

Share

Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer

Ask about this paper

Abstract

Discussion

Cite This Study

Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading